

## CURRICULUM VITAE

**INVESTIGATOR NAME** José María Descalzo  
**INVESTIGATOR NATIONALITY** Argentina  
**LICENSE NUMBER** MP 95601  
**STUDY LOCATION ADDRESS:** **Centro de Investigaciones Médicas Mar del Plata**  
Av. Colón 3083, 1º, 4º, 5º y 7º piso. Mar del Plata. Bs. As.  
Argentina  
Tel: 223 491-7628 / 495-6654 – Fax: 223 4957241

### **EDUCATION: University, date and title obtained**

2010 Universidad Nacional de Rosario, Facultad de Ciencias Médicas  
Title: Physician

### **GRADUATE: Specialty, dates, names of institutions**

2014-2017 Specialist in Medical clinic, complete Residence in Hospital Privado de Comunidad. Mar del Plata  
2017-2020 Specialist in Clinical Oncologist, complete residence in Hospital Privado de Comunidad. Mar del Plata  
2020 Oncology specialist. Awarded by Colegio de Médicos de la Pcia de Buenos Aires  
Feb 2023 Training in good clinical practice NIDA  
2023 Clinical Research Course taught by Asociación Argentina de Oncología Clínica (AAOC) y Grupo Argentino de Investigación Clínica en Oncología (GAICO)

### **PROFESSIONAL EXPERIENCE**

#### **Current work:**

May 2021 Oncology service staff Sanatorio Belgrano Mar del Plata  
May 2021 Oncology service staff Centro de Estudios Digestivos, Mar del Plata  
May 2021 Oncology service staff Oncología Clínica Mitre Mar del Plata  
May 2021 Oncology service staff, Htal Ferreyra, Necochea  
-Oncologist Sub Investigator Centro de Investigaciones Médicas Mar del Plata Since Feb 2023

#### **Previous work:**

2010-2013 External guard service. Hospital Privado Regional del Sur, Bariloche, Rio Negro Argentina

### **PROFESSIONAL EXPERIENCE IN CLINICAL RESEARCH**

RAGNAR, Phase III Patients with metastatic Prostate Ca. Sub Investigator 2019-2020  
MO-29872, Phase III. Advanced or recurrent NSCLC not eligible for Platinum. Sub Investigator 2019-2020  
CA-209-901, Phase III, Previously Untreated Unresectable or Metastatic Urothelial Carcinoma. Sub Investigator 2019-2020  
KEYNOTE-671, Phase III, Patients with stage IIB or IIIA NSCLC. Sub Investigator 2019-2020  
-G042784 LIDERA Phase III Breast cancer. Since 2022 Sub Investigator  
-D9268C00001 TROPION-01. Phase III Unresectable Breast cancer or metastatic hormone receptor positive, HER2 negative. Since 2022. Sub Investigator  
-D926PC00001 TROPION-02. Phase III Locally recurrent inoperable or metastatic triple-negative breast cancer, who are not candidates for PD-1/PD-L1 inhibitor therapy. Since 2023 Sub Investigator  
2023-I8F-MC-GPIJ Phase III Reduction of Morbidity and Mortality in Adults with Obesity. Sub Investigator  
2023-STABILIZE Phase III Chronic kidney disease and hyperkalaemia Sub-Investigator

2023- J2A-MC-GZGU Phase III Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Metformin Sub Investigator  
2024 -AMG20210031. Phase III. Unresectable or Metastatic Melanoma. Sub Investigator  
2024-OPI1250-301 (OPERA-01) Phase III, Estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer. Sub Investigator  
2024- AMG20220083-VERBENA Phase III Resected Stage III or IV Melanoma Subjects in the Adjuvant Setting Sub Investigator

**DATE:**

15/JAN/24

**SIGNATURE:**

JOSE MARIA DESCALZO  
Esp. Oncología  
M. P. 95.601